Provenge Review In 2008 Hinges On IMPACT Interim Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will accept positive interim analysis of survival from the Phase III trial for registration of the therapeutic cancer vaccine, Dendreon confirms.